Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.48 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205504 | 0.91 | CHEK2 (0.49) | CHEK2HCRTR1HCRTR2F2RL3KDM4E | |
| SCHEMBL7399721 | 0.82 | CHEK2 (0.61) | CHEK2HCRTR1HCRTR2NPC1RAB9A | |
| SCHEMBL31648332 | 0.82 | CHEK2 (0.53) | CHEK2HCRTR1HCRTR2HDAC8ATM | |
| SCHEMBL6609250 | 0.80 | CHEK2 (0.56) | CHEK2HCRTR1HCRTR2KDM4ENPC1 | |
| SCHEMBL8703528 | 0.79 | TP53 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL6615093 | 0.79 | HCRTR1 (0.58) | CHEK2HCRTR1HCRTR2 | |
| SCHEMBL30428901 | 0.78 | PRMT5 (0.50) | CHEK2HCRTR1HCRTR2PRMT5 | |
| SCHEMBL6608981 | 0.78 | HCRTR1 (0.69) | CHEK2HCRTR1HCRTR2KDM4E | |
| SCHEMBL5150212 | 0.78 | ALOX5AP (0.50) | CHEK2F2RL3 | |
| SCHEMBL5150218 | 0.78 | ALOX5AP (0.50) | CHEK2F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1819693-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006057868-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062271-A1 | Antithrombotic Diamides | TFPI, SERPINC1, TFPI2 | CHEK2 4253/4885HCRTR1 4782/4885HCRTR2 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.